Therapeutic-loaded lipid nanostructures and brain diseases

Nanomedicine and the Nervous System

Volumn , Issue , 2012, Pages 264-285

  Bondì, Maria Luisa ^a   Craparo, Emanuela Fabiola ^b  

^a CNR   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84936869091     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (36)

1. Alam, M.I., S. Beg, A. Samad, S. Baboota, K. Kohli, J. Ali, A. Ahuja and M. Akbard. 2010. Strategy for effective brain drug delivery. Eur. J. Pharm. Sci. 40: 385-403.
2. Almeida, A.J. and E. Souto. 2007. Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv. Drug Del. Rev. 59: 478-490.
3. Beduneau, A., P. Saulnier and J.P. Benoit. 2007. Active targeting of brain tumors using nanocarriers. Biomaterials 28: 4947-4967.
4. Blasi, P., S. Giovagnoli, A. Schoubben, M. Ricci and C. Rossi. 2007. Solid lipid nanoparticles for targeted brain drug delivery. Adv. Drug Del. Rev. 59: 454-477.
5. Bondì, M.L., G. Montana, E.F. Craparo, P. Picone, G. Capuano, M. Di Carlo and G. Giammona. 2009. Ferulic acid-loaded lipid nanostructures as drug delivery systems for Alzheimer’s disease: preparation, characterization and cytotoxicity studies. Current Nanosci. 5: 26-32.
6. Bondì, M.L., E.F. Craparo, G. Giammona and F. Drago. 2010. Brain-targeted solid lipid nanoparticles (SLNs) containing riluzole: preparation, characterisation and biodistribution. Nanomedicine 5: 25-32.
7. Bondì, M.L. and E.F. Craparo. 2010. Solid lipid nanoparticles for applications in gene therapy: a review of the state of the art. Expert Opin. Drug Del. 7: 7-18.
8. Brioschi, A.M., S. Calderoni, G.P. Zara, L. Proano, M.R. Gasco and A. Mauro. Solid lipid nanoparticles for brain tumors therapy: state of the art and novel challenger. pp. 193-223 In: H.S. Sharma [Eds.] 2010. Progress in Brain Research.
9. Byrne, J.D., T. Betancourt and L. Brannon-Peppas. 2008. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv. Drug Del. Rev. 60: 1615-1626.
10. Chattopadhyay, N., J. Zastre, H.L. Wong, X.Y. Wu and R. Bendayan. 2008. Solid lipid nanoparticles enhance the delivery of the HIV protease inhibitor, atazanavir, by a human brain endothelial cell line. Pharm. Res. 25: 2262-2271.
11. Craparo, E.F., M.L. Bondì, G. Pitarresi and G. Cavallaro. Nanoparticulate systems for drug delivery and targeting to the central nervous system. CNS Neuroscience & Therapeutics (in press) doi:10.1111/j.1755-5949.2010.00199.x
12. Denora, N., A. Trapani, V. Laquintana, A. Lopedota and G. Trapani. 2009. Recent advances in medicinal chemistry and pharmaceutical technology-strategies for drug delivery to the brain. Current Topics in Medicinal Chemistry 9: 182-196.
13. Fernandes, C., U. Soni and V. Patravale. 2010. Nano-interventions for neurodegenerative disorders, Pharmacological Research 62: 166-178.
14. Gabathuler, R. 2010. Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases. Neurobiology of Disease 37: 48-57.
15. Gupta, U. and N.K. Jain. 2010. Non-polymeric nano-carriers in HIV/AIDS drug delivery and targeting. Adv. Drug Del. Rev. 62: 478-490.
16. Gupta, Y., A. Jain and S.K. Jain. 2007. Transferrin-conjugated solid lipid nanoparticles for enhanced delivery of quinine dihydrochloride to the brain. J. Pharm. Pharmacol. 59: 935-940.
17. Hu, Y., J. Xie, T.Y. Wah and C.-H. Wang. 2007. Effect of PEG conformation and particle size on the cellular uptake efficiency of nanoparticles with the HepG2 cells. J. Control Release 118: 7-17.
18. Huang, G., N. Zhang, X. Bi and M. Dou. 2008. Solid lipid nanoparticles of temozolomide: Potential reduction of cardial and nephric toxicity. Int. J. Pharm. 355: 314-320.
19. Joshi, M.D. and R.H. Müller. 2009. Lipid nanoparticles for parenteral delivery of actives. Eur. J. Pharm. Biopharm. 71: 161-172.
20. Juillerat-Jeanneret, L. 2008. The targeted delivery of cancer drugs across the blood-brain barrier: chemical modifications of drugs or drug-nanoparticles? Drug Discov. Today 13: 1099-1106.
21. Kaur, I.P., R. Bhandari, S. Bhandari and V. Kakkar. 2008. Potential of solid lipid nanoparticles in brain targeting. J. Control Release 127: 97-109.
22. Koo, Y.-E.L., G.R. Reddy, M. Bhojani, R. Schneider, M.A. Philbert, A. Rehemtulla, B.D. Ross and R. Kopelman. 2006. Brain cancer diagnosis and therapy with nanoplatforms. Adv. Drug Del. Rev. 58: 1556-1577.
23. Koziara, J.M., P.R. Lockman, D.D. Allen and R.J. Mumper. 2004. Paclitaxel nanoparticles for the potential treatment of brain tumors. J. Control Rel. 99: 259-269.
24. Kuo, Y.C. and F.L. Su. 2007. Transport of stavudine, delavirdine, and saquinavir across the blood-brain barrier by polybutylcyanoacrylate methyl methacrylate sulfopropyl methacrylate and solid lipid nanoparticles. Int. J. Pharm. 340: 143-152.
25. Lockman, P.R., M.O. Oyewumi, J.M. Koziara, K.E. Roder, R.J. Mumper and D.D. Allen. 2003. Brain uptake of thiamine-coated nanoparticles. J. Control Release 93: 271-282.
26. Manjunath, K. and V. Venkateswarlu. 2005. Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. J. Control. Release 107: 215-228.
27. Olivier, J.-C. and M.P. de Oliviera. 2007. Nanoparticulate systems for central nervous system drug delivery. pp. 281-290. In: M. Deleers, Y. Pathak, Y.D. Thassu. [eds.] Nanoparticulate Drug Delivery Systems. Informa Healthcare, new York, USA.
28. Pardridge, W.M. 2005. Molecular biology of the blood-brain barrier. Mol. Biotechnol. 30: 57-70.
29. Park, J.H., S. Lee, J.H. Kim, K. Park, K. Kim and I.C. Kwon. 2008. Polymeric nanomedicine for cancer therapy. Progress in Polymer Science 33: 113-137.
30. Sarin, H. 2009. Recent progress towards development of effective systemic chemotherapy for the treatment of malignant brain tumors. J. Transl. Med. 7: 77.
31. Souto, E.B. and R.H. Müller. 2007. Lipid nanoparticles (Solid Lipid Nanoparticles and Nanostructured Lipid Carriers) for Cosmetic, Dermal, and Transdermal applications. pp. 213-233. In: M. Deleers, Y. Pathak, Y.D. Thassu [eds.] Nanoparticulate Drug Delivery Systems. Informa Healthcare, new York, USA.
32. Thomas, M.B. and M.A. Mansoor. 2009. Challenges and opportunities in CNS delivery of therapeutics for neurodegenerative diseases. Expert Opin. Drug Deliv. 6: 211-25.
33. Wang, J.X., X. Sun and Z.R. Zhang. 2002. Enhanced brain targeting by synthesis of 3',5'-dioctanoyl-5-fluoro-2'-deoxyuridine and incorporation into solid lipid nanoparticles. Eur. J. Pharm. Biopharm. 54: 285-290.
34. Weiss, J., E.A. Decker, D.J. McClements, K. Kristbergsson, T. Helgason and T. Awad. 2008. Solid lipid nanoparticles as delivery systems for bioactive food components. Food Biophisics 3: 146-154.
35. Yang, S., J. Zhu, Y. Lu, B. Liang and C. Yang. 1999. Body distribution of camptothecin solid lipid nanoparticles after oral administration. Pharm. Res. 16: 751-757.
36. Yang, H. 2010. Nanoparticle-Mediated Brain-Specific Drug Delivery, Imaging, and Diagnosis. Pharm. Res. 27: 1759-1771.